Trial Profile
A prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2021
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications Severe acute respiratory syndrome
- Focus Therapeutic Use
- 23 Nov 2021 New trial record
- 02 Nov 2021 Results published in the Journal of Thoracic Oncology